OTI-0726 would certainly have a meaningful clinical effect in patients. If you look at the underlying pathology, the longer the clotting process has progressed, the more stable the clot becomes. Attacking the clot earlier could abort or dampen the thrombotic process.
I am not perfectly systematic when it comes to recommending rescue aspirin to my patients. When aspirin comes up in conversation, I will mention that a rescue aspirin is a good idea in the event of a heart attack. Since the guideline update my patients and I have been discussing aspirin more often
The major strength of this product is that it’s anti-platelet effects begin within 2 minutes. Asprihale® would begin inhibiting platelet aggregation much faster than our standard chewable aspirin
I don’t need to see outcomes data to believe that this product will help my patients. The chain of logic that connects early aspirin administration and better outcomes to faster platelet inhibition is sufficient for me to prescribe Asprihale®
Get in touch with us for more info about OtiTopic, Inc.